Business
Completion of Evaluation Programme with Bio-Techne
Completion of Evaluation Programme with Bio-Techne.
About this update from Cizzle Biotechnology Holdings Plc
[{"type":"text","content":"\n\nCizzle Biotechnology Holdings plc\n \n(\"Cizzle\" or the \"Company\")\n \nCizzle and Bio-Techne Announce Completion of Evaluation Programme for Detection of CIZ1B Using ProteinSimple Branded Simple WesternTM Platform\nLondon/Minneapolis/September 19, 2023 -- Bio-Techne Corporation (NASDAQ: TECH) and Cizzle Biotechnology Holdings plc, the UK-based diagnostics developer, are pleased to announce recent progress evaluating specific monoclonal antibodies for Cizzle's CIZ1B cancer biomarker. Cizzle has successfully completed an evaluation programme aimed at assessing the feasibility of using the Simple Western platform from ProteinSimple (a Bio-Techne brand) for high throughput detection of the CIZ1B cancer biomarker which may be useful in the detection of early-stage lung cancer.\nThe global lung cancer screening market is projected to grow from US$2.80 billion in 2021 to US$4.85 billion in 2028, representing a CAGR of 8.1% during the forecast period*. Furthermore, in 2021 the United States Preventive Services Task Force (USPSTF) updated its lung cancer screening guidelines** for annual screening with low-dose computed tomography (\"LDCT\"), reducing the lower limit of the screening age from 55 to 50 years and the minimum smoking history from 30 to 20 pack-years. Under the new guidelines, 14.5 million Americans may be eligible for annual screening with LDCT and other early-lung cancer screening tests which is estimated could save an additional 10,000-20,000 lives each year.\nAllan Syms, Executive Chairman of Cizzle, commented: \"We are very pleased to be working with Bio-Techne, a global leader in bioscience solutions. We believe the Simple Western platform is an excellent fit for use in our development of a high throughput assay for the detection of the Company's CIZ1B biomarker. Cizzle has shown that CIZ1B is highly associated with lung cancer at its earliest stage when surgical or other therapeutic intervention is possible, which is key to saving lives. We look forward to building on this important project as we push forward in bringing our novel diagnostic solution to market.\"\n \nWill Geist, President of Bio-Techne's Protein Sciences Segment, commented: \"We are pleased that Cizzle has chosen the Simple Western platform for the development of its novel biomarker. The automation, sensitivity, small sample inpu...